Article · 9 Nov 2026
Conference abstract
Developing lead compounds that restore death sensitivity to trophic withdrawal in MYCN-initiated death resistant cells
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Embryonic cancer arises from postnatal persistent embryonal remnant or rest cells that are uniquely characterized by the absence of p53 mutations. We have showed that c-Myc and Myc N-overexpressing perinatal murine pre-B lymphocytes are resistant to apoptosis induced by interleukin-7 (IL-7) withdrawal and are associated with decreased p53 induction. From an initial library of 40,000 compounds, we generated a list of 56 hit compounds that displayed activity against Myc N-expressing pre-B cells in the absence of IL-7, but had minimal effect on cells in the presence of trophic factor. One of the lead compound, PB-798, reduced ganglia cell growth only in the absence of NGF and restored sensitivity to NGF withdrawal-induced cell death in myc N-expressing ganglia cells from TH-myc N homozygous mice, suggest that PB-798 can restore death sensitivity to trophic withdrawal in Myc-driven persistent rest cells. Furthermore, we investigated the potential mechanisms of cell death initiated by PB-798. By western blot, we found PB-798 treatment after 72 hours at 10 μM significantly reduced myc N protein levels in myc N-expressing clone F cells. We performed Affymetrix gene arrays and nanostring analysis to investigate the key genes/signaling pathways involved in the mechanism of cell death. We found that seven signaling pathways were significantly enriched. We have now identified 7 target genes in steroid biosynthesis and 5 target genes in JAK/STAT signaling pathways as the potential molecular targets for PB-798 drug action. Importantly, we have tested the efficacy of PB-798 in Myc N over-expression zebrafish neuroblastoma model and found that PB-798 significantly inhibits myc N-induced neuroblastic hyperplasia in the inter-renal gland (IRG) of this Myc N over-expression zebrafish model. PB-798 will be further tested in in vivo models of myc-driven tumor initiation such as the Eμ-Myc mouse model of lymphoma and the TH-myc N neuroblastoma mouse model.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Pharmacology.
Article · 23 Feb 2026
A Thorough Overview of Polycystic Ovary Syndrome (PCOS) in Female Rats
Article · 19 Dec 2025
Theoretical Pharmacology: Understanding Drug Action Through Models and Principles
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pharmacology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Belamy B Cheung”
- BylineArticles whose byline prints “Owen Tan”
- BylineArticles whose byline prints “Jessica Koach”
- BylineArticles whose byline prints “Selina Sutton”
- BylineArticles whose byline prints “Sonya M Diakiw”
- BylineArticles whose byline prints “Carol G Au”
- BylineArticles whose byline prints “Kacper Jankowski”
- BylineArticles whose byline prints “Toby N Trahair”
